F2G appoints Dr Patrick Vink as Chairman
Brings successful track record of building and growing global businesses
MANCHESTER, UK & VIENNA, AUSTRIA – 8 April 2019 – F2G Ltd, the European biotech company developing novel therapies for life-threatening fungal infections, today announces the appointment of Dr Patrick Vink as Chairman of the Board of Directors with immediate effect. Dr Vink replaces Dr Richard J. White who stood down in December 2018.
Dr Vink has over 30 years of experience in the biotechnology and pharmaceutical industry and has a successful track record of building and growing global pharmaceutical businesses. He was previously Chief Operating Officer at Cubist Pharmaceuticals Inc, with responsibility for global commercial operations, and the development and implementation of long- and short-term strategy. During his term, Cubist was acquired by Merck & Co. Prior to Cubist, he was Head of the Global Hospital Business at Mylan Inc. as part of the global executive team. Before this, he was Head of Global Biopharmaceuticals at Sandoz (division of Novartis) and held senior positions at Biogen Inc Sanofi-Synthelabo, and Numico.